Stockscreener 앱 받기
33.12
2.56%
0.7711
전일 마감가:
$32.35
열려 있는:
$32.5
하루 거래량:
370.70K
Relative Volume:
0.51
시가총액:
$1.83B
수익:
$2.50M
순이익/손실:
$-131.12M
주가수익비율:
-11.65
EPS:
-2.8431
순현금흐름:
$-112.73M
1주 성능:
+11.19%
1개월 성능:
+36.71%
6개월 성능:
-17.81%
1년 성능:
+173.75%
1일 변동 폭
$31.87
$33.49
1주일 범위
$29.41
$33.49
52주 변동 폭
$12.44
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
명칭
Maze Therapeutics Inc
전화
(650) 850-5070
주소
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
33.12 | 1.79B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
522.00 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.79 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.13 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.99 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.13 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-03-10 | 개시 | Mizuho | Outperform |
| 2025-12-04 | 개시 | Wells Fargo | Overweight |
| 2025-11-14 | 개시 | Raymond James | Outperform |
| 2025-09-02 | 개시 | BTIG Research | Buy |
| 2025-07-23 | 개시 | H.C. Wainwright | Buy |
| 2025-07-08 | 개시 | Wedbush | Outperform |
모두보기
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
[Form 4] Maze Therapeutics, Inc. Insider Trading Activity - Stock Titan
Maze Therapeutics (MAZE) CEO’s family trusts sell 34,501 shares under 10b5-1 plan - Stock Titan
Enterprise value to EBITDA forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Form 144 Maze Therapeutics For: 1 July By Investing.com - Investing.com UK
Form 4 Maze Therapeutics Inc For: 1 July By Investing.com - Investing.com Nigeria
MAZE (NASDAQ: MAZE) sale notice: 46,892 shares via option exercise - Stock Titan
Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares - Investing.com
Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares By Investing.com - Investing.com India
Maze Therapeutics (MAZE) CSBO sells 7,500 shares under Rule 10b5-1 plan - Stock Titan
MAZE (MAZE) trusts sell tens of thousands of common shares May–June 2026 - Stock Titan
Maze Therapeutics (MAZE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Enterprise value to revenue forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Maze Therapeutics (MAZE) Gains 2.18% as Shares Test Key Resistance at $30.5Volatility Stop - dars.gov.et
Price to book forward of Maze Therapeutics, Inc. – BOATS:MAZE - TradingView
Price to earnings forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Enterprise value to revenue forward of Maze Therapeutics, Inc. – BOATS:MAZE - TradingView
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? - Yahoo Finance
Maze Therapeutics (MAZE) Rebounds This Week, Is The Upside Already Priced In? - Sahm
MAZE Forecast — Price Target — Prediction for 2027 - TradingView
GHRS Stock Price and Chart — NASDAQ:GHRS - TradingView
Maze Therapeutics, Inc. Actuals & Estimates (NASDAQ:MAZE) - TradingView
MAZE Stock Price, Quote & Chart - ChartMill
Maze Therapeutics Inc (MAZE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maze Therapeutics (MAZE) CEO sells 27,858 shares under 10b5-1 trading plan - Stock Titan
Maze Therapeutics Inc (MAZE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mizuho Securities Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $97 - Moomoo
Analyst Reaffirms Buy on Maze with Unchanged $110 Price Target, Citing Strong HORIZON Data and Favorable Risk-Reward - TipRanks
Maze Therapeutics (MAZE) price target increased by 11.37% to 44.12 - MSN
Maze Therapeutics (MAZE) Gains 3.38% as Biotech Stock Tests Key Resistance LevelsFibonacci Entry Signals - dars.gov.et
Maze Therapeutics Inc (MAZE) Institutional Confidence - TradingKey
Maze Therapeutics Inc (MAZE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maze Therapeutics Inc (MAZE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maze Therapeutics Inc (MAZE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Maze Therapeutics Inc (MAZE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MAZE Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressGuidance Revision Trend - newsline.com
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk - Yahoo Finance
MAZE Q1 2026 Earnings: Narrower Loss Surprises Analysts Amid Pipeline ProgressEarnings Acceleration Picks - lwvtexas.org
MAZE Q1 2026 Earnings: Smaller-Than-Expected Loss Drives Positive Stock ReactionEPS Revision Trend - newsline.com
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor - TipRanks
Maze Therapeutics (MAZE) director receives grant of 18,000 stock options exercisable at $23.58 - Stock Titan
Director Richard Scheller receives 18,000 Maze Therapeutics (MAZE) stock options - Stock Titan
Maze Therapeutics (MAZE) director Herve Hoppenot awarded 18,000 stock options at $23.58 - Stock Titan
18,000 Maze Therapeutics (MAZE) options granted to director Andrews - Stock Titan
Maze Therapeutics (MAZE) shareholders elect directors and ratify Ernst & Young - Stock Titan
MAZE: Lead assets show strong efficacy and safety, with pivotal trials and key data readouts set for 2026–2027 - TradingView
MAZE: Directors and auditor ratified by majority vote; no shareholder questions submitted - TradingView
MAZE: Both director nominees and the auditor appointment were approved by majority vote - TradingView
MAZE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockBasic EPS Analysis - newsline.com
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now - Insider Monkey
Maze Therapeutics Inc (MAZE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Maze Therapeutics Inc 주식 (MAZE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO |
Jul 01 '26 |
Sale |
29.90 |
14,609 |
436,864 |
0 |
| Coloma Jason V | Chief Executive Officer |
Jul 01 '26 |
Sale |
29.98 |
34,501 |
1,034,253 |
23,337 |
1.21%
3.14%
자본화:
|
볼륨(24시간):